

# Oncology Pharma Limited

Unaudited Abbreviated Accounts

for the Year Ended 30 September 2013

RWB CA Limited  
Northgate House  
North Gate  
New Basford  
Nottingham  
NG7 7BQ

Oncology Pharma Limited  
Contents

Abbreviated Balance Sheet	<div></div>	<div></div>	<u>1</u>
Notes to the Abbreviated Accounts	<div></div>		<u>2 to 3</u>

**Oncology Pharma Limited**  
**(Registration number: 06926307)**  
**Abbreviated Balance Sheet at 30 September 2013**

	Note	2013 £	2012 £
<b>Fixed assets</b>			
Tangible fixed assets	<u>2</u>	194	216
<b>Current assets</b>			
Debtors		6,901	2,497
Cash at bank and in hand		74	77
		6,975	2,574
Creditors: Amounts falling due within one year		(6,862)	(3,606)
Net current assets/(liabilities)		113	(1,032)
Total assets less current liabilities		307	(816)
Provisions for liabilities		(39)	-
Net assets/(liabilities)		<u>268</u>	<u>(816)</u>
<b>Capital and reserves</b>			
Called up share capital	<u>3</u>	100	100
Profit and loss account		168	(916)
Shareholders' funds/(deficit)		<u>268</u>	<u>(816)</u>

For the year ending 30 September 2013 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 25 April 2014 and signed on its behalf by:

.....  
Mr N O Nagel  
Director

The notes on pages 2 to 3 form an integral part of these financial statements.

**Oncology Pharma Limited**  
**Notes to the Abbreviated Accounts for the Year Ended 30 September 2013**  
*..... continued*

**1 Accounting policies**

**Basis of preparation**

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

**Turnover**

Turnover represents amounts chargeable, net of value added tax, in respect of the sale of goods and services to customers.

**Depreciation**

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

<b>Asset class</b>	<b>Depreciation method and rate</b>
Office equipment	25% reducing balance or straight line basis

**Deferred tax**

Provision is made using the liability method for taxation which is deferred due to depreciation allowances and other timing differences. No deferred taxation is recognised unless the amounts are material.

**Hire purchase and leasing**

Rentals payable under operating leases are charged in the profit and loss account on a straight line basis over the lease term.

**Financial instruments**

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability in the balance sheet. The corresponding dividends relating to the liability component are charged as interest expense in the profit and loss account.

**Oncology Pharma Limited**  
**Notes to the Abbreviated Accounts for the Year Ended 30 September 2013**  
*..... continued*

**2 Fixed assets**

	<b>Tangible assets £</b>	<b>Total £</b>
<b>Cost</b>		
At 1 October 2012	454	454
Additions	<u>37</u>	<u>37</u>
At 30 September 2013	<u>491</u>	<u>491</u>
<b>Depreciation</b>		
At 1 October 2012	238	238
Charge for the year	<u>59</u>	<u>59</u>
At 30 September 2013	<u>297</u>	<u>297</u>
<b>Net book value</b>		
At 30 September 2013	<u>194</u>	<u>194</u>
At 30 September 2012	<u>216</u>	<u>216</u>

**3 Share capital**

**Allotted, called up and fully paid shares**

	<b>2013</b>		<b>2012</b>	
	<b>No.</b>	<b>£</b>	<b>No.</b>	<b>£</b>
Ordinary shares of £1 each	100	100	100	100
	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>

Page 3

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.